Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 4 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 385Carcinoma, Non-Small-Cell Lung 243Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 192Neoplasms 178Colorectal Neoplasms 161Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 127Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 114Squamous Cell Carcinoma of Head and Neck 107Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 88Carcinoma, Hepatocellular 80Triple Negative Breast Neoplasms 76Esophageal Neoplasms 76Endometrial Neoplasms 75Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 55Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

relugolix 1apalutamide 1abiraterone 1Prednisone 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-Resistant Prostate Cancer × Genitourinary × Clear all
NCT06318273 2026-04-08

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1 Recruiting
230 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03137758 2020-03-09

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Pellficure Pharmaceuticals, Inc

Phase 1 Terminated
12 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡